Streetbeat News

ELTP

Elite Pharmaceuticals, Inc.

Employees

Industry

Pharmaceutical Preparation Manufacturing

Open

0.50

Mkt cap

551M

Volume

322K

High

0.53

P/E Ratio

-51.55

52-wk high

0.75

Low

0.50

Div yield

N/A

52-wk low

0.12

Elite Pharmaceuticals has launched a generic version of Norco, a pain management medication, in various dosages. This development could impact the company's market presence and financial performance.

Portfolio Pulse from

December 02, 2024 | 11:15 am

The article highlights two smaller companies, a small cap and a microcap, that have received Zacks Outperform ratings, indicating potential for strong performance.

Portfolio Pulse from

November 25, 2024 | 9:00 pm

Elite Pharmaceuticals reported a decline in Q2 earnings but experienced strong revenue growth due to new product launches and strategic acquisitions. Despite the net loss, the stock price increased.

Portfolio Pulse from

November 18, 2024 | 6:15 pm

Elite Pharmaceuticals has received FDA approval for a generic version of Vyvanse, a medication for ADHD. This approval allows Elite to manufacture and distribute the drug in various strengths.

Portfolio Pulse from

November 18, 2024 | 11:15 am

Elite Pharmaceuticals, Inc. (ELTP) held its Q2 2025 earnings conference call, discussing financial results and company performance.

Portfolio Pulse from

November 16, 2024 | 8:45 pm

Elite Pharmaceuticals, Inc. reported a 33% increase in revenues for the second quarter of fiscal year 2025, ending September 30, 2024, with total revenues of $18.9 million. A conference call is scheduled for November 15, 2024, to discuss these results.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

Elite Pharmaceuticals, Inc. will release its second quarter financial results for fiscal year 2025 on November 14, 2024, and will host a conference call on November 15, 2024, to discuss these results and provide a corporate update.

Portfolio Pulse from

November 07, 2024 | 12:15 pm

Elite Pharmaceuticals (OTC:ELTP) reported a 17.03% increase in Q1 sales, up from $7.67 million to $8.98 million YoY.

Portfolio Pulse from mahesh@benzinga.com

August 14, 2023 | 8:57 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.